|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C07K 16/30 | (2006.01) | ||
| A61K 31/337 | (2006.01) | ||
| A61K 31/555 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3357509 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17164584.9 |
| Date of filing the European patent application | 2017-04-03 | |
| (97) | Date of publication of the European application | 2018-08-08 |
| (45) | Date of publication and mention of the grant of the patent | 2021-06-09 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201762455114 P | 2017-02-06 | US |
| (72) |
NICODEMUS, Christopher F. , US
MADIYALAKAN, Ragupathy , CA
|
| (73) |
Oncoquest Pharmaceuticals Inc. ,
670-21 Sannae-ro,
Sannae-myeon, Miryang-Si,
KR
|
| (54) | TREATMENT OF CANCER WITH THERAPEUTIC MONOCLONAL ANTIBODY SPECIFIC FOR A TUMOR ASSOCIATED ANTIGEN AND AN IMMUNE ADJUVANT |
| TREATMENT OF CANCER WITH THERAPEUTIC MONOCLONAL ANTIBODY SPECIFIC FOR A TUMOR ASSOCIATED ANTIGEN AND AN IMMUNE ADJUVANT |